A study of TMC435 plus PegIFN and RBV in Chronic HCV Version 2.0

• Research type

  Research Study

• Full title

  A Phase 3, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of TMC435 plus Pegylated Interferon alfa-2a and Ribavirin Administered for 12 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1 HCV Infection.

• IRAS ID

  136502

• Contact name

  David Bell

• Contact email

  David.Bell@ggc.scot.nhs.uk

• Sponsor organisation

  SGS – Belgium N.V.

• Eudract number

  2012-004905-29

• Clinicaltrials.gov Identifier

  NCT01846832

• REC name

  West of Scotland REC 1

• REC reference

  13/WS/0211

• Date of REC Opinion

  4 Nov 2013

• REC opinion

  Further Information Favourable Opinion